carvedilol has been researched along with Systolic Heart Failure in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the impact of carvedilol dose changes on the ventricular arrhythmia event rates for patients > 18 years of age with systolic heart failure and examines dose dependent effects of carvedilol withdrawal in dose reduction and discontinuation subgroups." | 7.81 | Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure. ( Anaya, P; Brouse, SD; Charnigo, RJ; Kido, K; Macaulay, TE, 2015) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 7.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| "To determine whether carvedilol can be safely up-titrated before hospital discharge, we studied 372 consecutive patients with systolic heart failure who were being treated with carvedilol." | 7.74 | Rapid carvedilol up-titration in hospitalized patients with systolic heart failure. ( Alhama, M; Barrueco, N; Castillo, I; Datino, T; Fernández-Avilés, F; Martínez-Sellés, M, 2008) |
| "Carvedilol treatment for 4 months resulted in a significant improvement of RVEF, which paralleled the improvement of LVEF and the decreasing of TNF-alpha and IL-6 levels in patients with systolic HF." | 6.73 | Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. ( Aktoz, M; Buyuklu, M; Kurum, T; Tatli, E, 2008) |
| "We performed a post hoc analysis of pooled individual patient data (n=4217) from 2 multinational, double-blinded, placebo-controlled, randomized trials, CAPRICORN (Carvedilol Postinfarct Survival Control in Left Ventricular Dysfunction Study) and COPERNICUS (Carvedilol Prospective Randomized, Cumulative Survival study)." | 6.25 | Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. ( Beck, GJ; Berl, T; Chartyan, DM; Cheung, AK; Chonchol, M; Cooper, C; Henrich, WL; Himmelfarb, J; Iyengar, M; Lukas, MA; Wali, RK; Weir, MR, 2011) |
| "Treatment with carvedilol directly improved the systolic function of the right and left ventricles." | 5.48 | Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. ( Hirata, Y; Inaba, T; Ishikawa, Y; Komuro, I; Saito, A; Soma, K; Yao, A, 2018) |
| "We analyzed outcomes in SHIFT patients with systolic heart failure who were prescribed β-blockers (carvedilol, bisoprolol, metoprolol, or nebivolol) with ivabradine or placebo." | 5.20 | Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population. ( Bocchi, EA; Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L, 2015) |
| "This study evaluates the impact of carvedilol dose changes on the ventricular arrhythmia event rates for patients > 18 years of age with systolic heart failure and examines dose dependent effects of carvedilol withdrawal in dose reduction and discontinuation subgroups." | 3.81 | Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure. ( Anaya, P; Brouse, SD; Charnigo, RJ; Kido, K; Macaulay, TE, 2015) |
| "Increased inflammatory activation observed only in heart failure patients not improving left-ventricular function after carvedilol may indicate that inflammation, either as a direct cause or as a consequence, is associated with progressive ventricular dysfunction." | 3.79 | Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. ( Alfieri, AB; Briceno, L; Calori, G; Colombo, B; Corti, A; Fragasso, G; Lattuada, G; Locatelli, M; Maranta, F; Margonato, A; Perseghin, G; Salerno, A; Spoladore, R, 2013) |
| "To determine whether carvedilol can be safely up-titrated before hospital discharge, we studied 372 consecutive patients with systolic heart failure who were being treated with carvedilol." | 3.74 | Rapid carvedilol up-titration in hospitalized patients with systolic heart failure. ( Alhama, M; Barrueco, N; Castillo, I; Datino, T; Fernández-Avilés, F; Martínez-Sellés, M, 2008) |
| "Carvedilol treatment for 4 months resulted in a significant improvement of RVEF, which paralleled the improvement of LVEF and the decreasing of TNF-alpha and IL-6 levels in patients with systolic HF." | 2.73 | Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure. ( Aktoz, M; Buyuklu, M; Kurum, T; Tatli, E, 2008) |
| "8 months was analysed with respect to beta blocker dosing and resting HR." | 1.48 | Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy. ( Corletto, A; Frankenstein, L; Fröhlich, H; Hochadel, M; Katus, HA; Kilkowski, C; Senges, J; Täger, T; Winkler, R; Zahn, R, 2018) |
| "Treatment with carvedilol directly improved the systolic function of the right and left ventricles." | 1.48 | Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot. ( Hirata, Y; Inaba, T; Ishikawa, Y; Komuro, I; Saito, A; Soma, K; Yao, A, 2018) |
| "Carvedilol was initiated 3 days after admission (median); 594 patients (97%) were discharged alive, 27 (5%) without beta-blockers." | 1.36 | Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry. ( Alhama, M; Barrueco, N; Castillo, I; Datino, T; Fernández-Avilés, F; Martínez-Sellés, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corletto, A | 1 |
| Fröhlich, H | 1 |
| Täger, T | 1 |
| Hochadel, M | 1 |
| Zahn, R | 1 |
| Kilkowski, C | 1 |
| Winkler, R | 1 |
| Senges, J | 1 |
| Katus, HA | 1 |
| Frankenstein, L | 1 |
| Soma, K | 1 |
| Yao, A | 1 |
| Saito, A | 1 |
| Inaba, T | 1 |
| Ishikawa, Y | 1 |
| Hirata, Y | 1 |
| Komuro, I | 1 |
| Wikstrand, J | 1 |
| Wedel, H | 1 |
| Castagno, D | 1 |
| McMurray, JJ | 1 |
| Bagriy, AE | 1 |
| Schukina, EV | 1 |
| Samoilova, OV | 1 |
| Pricolota, OA | 1 |
| Malovichko, SI | 1 |
| Pricolota, AV | 1 |
| Bagriy, EA | 1 |
| Kido, K | 1 |
| Brouse, SD | 1 |
| Macaulay, TE | 1 |
| Charnigo, RJ | 1 |
| Anaya, P | 1 |
| Bocchi, EA | 1 |
| Böhm, M | 1 |
| Borer, JS | 1 |
| Ford, I | 1 |
| Komajda, M | 1 |
| Swedberg, K | 1 |
| Tavazzi, L | 1 |
| Rain, C | 1 |
| Rada, G | 1 |
| de Groote, P | 1 |
| Lamblin, N | 1 |
| Mouquet, F | 1 |
| Bauters, C | 1 |
| Martínez-Sellés, M | 2 |
| Datino, T | 2 |
| Alhama, M | 2 |
| Barrueco, N | 2 |
| Castillo, I | 2 |
| Fernández-Avilés, F | 2 |
| Fragasso, G | 2 |
| Salerno, A | 2 |
| Margonato, A | 2 |
| Nessler, J | 1 |
| Nessler, B | 1 |
| Kitliński, M | 1 |
| Stepniewski, M | 1 |
| Piwowarska, W | 1 |
| Fujimura, M | 1 |
| Akaike, M | 1 |
| Iwase, T | 1 |
| Yoshida, S | 1 |
| Sumitomo, Y | 1 |
| Yagi, S | 1 |
| Ikeda, Y | 1 |
| Hashizume, S | 1 |
| Aihara, K | 1 |
| Nishiuchi, T | 1 |
| Yasumura, Y | 1 |
| Matsumoto, T | 1 |
| Matsuda, N | 1 |
| Miranda, SM | 1 |
| Mesquita, ET | 1 |
| Dohmann, HF | 1 |
| Azevedo, JC | 1 |
| Barbirato, GB | 1 |
| Freire, Fde L | 1 |
| Ribeiro, ML | 1 |
| Nóbrega, AC | 1 |
| Coimbra, A | 1 |
| Mesquita, CT | 1 |
| Wali, RK | 1 |
| Iyengar, M | 1 |
| Beck, GJ | 1 |
| Chartyan, DM | 1 |
| Chonchol, M | 1 |
| Lukas, MA | 1 |
| Cooper, C | 1 |
| Himmelfarb, J | 1 |
| Weir, MR | 1 |
| Berl, T | 1 |
| Henrich, WL | 1 |
| Cheung, AK | 1 |
| Ong, HT | 1 |
| Kow, FP | 1 |
| Machida, M | 1 |
| Takechi, S | 1 |
| Fujimoto, T | 1 |
| Kakinoki, S | 1 |
| Nomura, A | 1 |
| Susa, T | 1 |
| Kobayashi, S | 1 |
| Tanaka, T | 1 |
| Murakami, W | 1 |
| Akashi, S | 1 |
| Kunitsugu, I | 1 |
| Okuda, S | 1 |
| Doi, M | 1 |
| Wada, Y | 1 |
| Nao, T | 1 |
| Yamada, J | 1 |
| Ueyama, T | 1 |
| Okamura, T | 1 |
| Yano, M | 1 |
| Matsuzaki, M | 1 |
| Wai, B | 1 |
| Kearney, LG | 1 |
| Hare, DL | 1 |
| Ord, M | 1 |
| Burrell, LM | 1 |
| Srivastava, PM | 1 |
| Spoladore, R | 1 |
| Maranta, F | 1 |
| Corti, A | 1 |
| Lattuada, G | 1 |
| Colombo, B | 1 |
| Locatelli, M | 1 |
| Calori, G | 1 |
| Briceno, L | 1 |
| Alfieri, AB | 1 |
| Perseghin, G | 1 |
| Hamaad, A | 1 |
| Lip, GY | 1 |
| Nicholls, D | 1 |
| MacFadyen, RJ | 1 |
| Albert, NM | 1 |
| Tatli, E | 1 |
| Kurum, T | 1 |
| Aktoz, M | 1 |
| Buyuklu, M | 1 |
| Rosenberg, J | 1 |
| Gustafsson, F | 1 |
| Remme, WJ | 1 |
| Riegger, GA | 1 |
| Hildebrandt, PR | 1 |
| de Boer, RA | 1 |
| van Veldhuisen, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction (Biomolecular and Clinical Study on IL-6, TNF-α, NT-ProBNP, MDA, LVEF, 6MWT, and KCCQ)[NCT05179070] | Phase 4 | 26 participants (Anticipated) | Interventional | 2021-09-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carvedilol and Systolic Heart Failure
| Article | Year |
|---|---|
Is carvedilol better than other beta-blockers for heart failure?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure, Systolic; Hospitalization; Human | 2015 |
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
Switching to once-daily evidence-based [beta]-blockers in patients with systolic heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Algorithms; Carbazoles; Carvedilol; Delayed-Action Preparations; Eviden | 2007 |
6 trials available for carvedilol and Systolic Heart Failure
| Article | Year |
|---|---|
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular Agents; Carv | 2015 |
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Chronic Disease; Creatinine; Double-Blind | 2011 |
Carvedilol improves uptake-1 in patients with systolic congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Exercise Test; | 2012 |
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Chroni | 2007 |
Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
Topics: Adult; Aged; Carbazoles; Carvedilol; Cytokines; Female; Heart Failure, Systolic; Humans; Male; Middl | 2008 |
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carve | 2008 |
18 other studies available for carvedilol and Systolic Heart Failure
| Article | Year |
|---|---|
Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy.
Topics: Adrenergic beta-Antagonists; Carvedilol; Cause of Death; Female; Follow-Up Studies; Germany; Heart F | 2018 |
Regular Treatment Strategy with a Large Amount of Carvedilol for Heart Failure Improves Biventricular Systolic Failure in a Patient with Repaired Tetralogy of Fallot.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Heart Failure, Systolic; Humans; | 2018 |
The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Delayed-A | 2014 |
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Drug | 2015 |
Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Dose-Response Relat | 2015 |
No gender survival difference in a population of patients with chronic heart failure related to left ventricular systolic dysfunction and receiving optimal medical therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Cardiomyopathies; | 2008 |
Rapid carvedilol up-titration in hospitalized patients with systolic heart failure.
Topics: Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Failure, Systolic; Hum | 2008 |
Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Chronic Disease; Heart | 2008 |
Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Analysis of Variance; Blood Flow Velocity; Carbazoles; Car | 2008 |
Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carvedilol; Dose-Response Relation | 2009 |
Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carbazoles; Carvedilol; Female; Heart Failure, | 2010 |
We should not hesitate to use beta-blockers for systolic heart failure with concomitant renal dysfunction.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure, Systolic; Humans; Propanolamines | 2010 |
Effects of short-term carvedilol on the cardiac sympathetic activity assessed by 123I-MIBG scintigraphy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adrenergic Fibers; Adult; Aged; Carbazoles; Carv | 2010 |
Beta-blockers for heart failure: why you should use them more.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Bisoprolol; Carbazoles; Carved | 2011 |
Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carve | 2012 |
Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Bisoprolol; Carbazole | 2012 |
Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Cohort Studies; Cytokines; Echocardiograp | 2013 |
ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Carbazoles; Carve | 2008 |